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Given that it is possible to extract DNA from the urine of
kidney transplant donors and recipients we studied whether
the donor HLA type can be determined from recipient urine.
This would be useful especially when there is limited
information on donors or when the transplant was
performed long ago when tissue typing was less precise.
We extracted and purified DNA from fresh urine and used the
standard HLA class I and class II PCR-SSP assays comparing
the findings to those obtained from peripheral blood of
donor and recipient HLA types. Using the urine of 31 renal
transplant recipients we assayed for the 140 known
mismatches, and all were detected in technically successful
assays with only a single false positive. This shows that urine
samples of transplant recipients can be used to generate
historical HLA typing information of the donor thereby aiding
post-transplant immunologic monitoring.
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Faced with the worldwide shortage of organs,1,2 patients are
increasingly traveling abroad for a transplant.3 Often there is
limited donor information when they return which can pose
management problems. One example is the lack of informa-
tion about the donor human leukocyte antigen (HLA) type.
In our practice, around 6% of all transplanted patients do not
have adequate donor HLA information. If this kidney is
subsequently lost, the lack of such information may be a
concern in retransplantation. It is a common practice not to
retransplant someone with a kidney that expresses mis-
matched antigens present on previously failed transplants,
even in the absence of HLA-specific antibodies. It would not
be possible to avoid such antigens if the initial donor HLA
type were unknown.
Second, there is increasing interest in post-trans-
plant immunological monitoring,4 both donor-specific anti-
bodies,5 and cellular reactivity.6 Having complete information
on the donor HLA type would assist the performance and
interpretation of such assays using surrogate cells or beads, if
donor material is not available.
Third, many donors of current long-lived transplants were
never tissue typed for class II and their class I typing was less
precise.
Donor and recipient DNA are detectable in urine from
kidney transplant recipients.7 With the development of tissue
typing techniques, requiring less DNA, we explored the
possibility of obtaining retrospective HLA-type information
on transplant donors from recipient urine. We believe this is
the first demonstration that this can be done.
RESULTS
DNA was extracted from urine specimens from 34 stable
renal transplant recipients, and 13 control individuals who
were free of known renal pathology and who had not
undergone renal transplantation. All eluates were subjected
to HLA class I (Figure 1) and II (online Supplementary
Information) typing. The recipient’s known HLA type
(as identified from HLA typing of a whole-blood sample
from the recipient) was subtracted from the HLA type
determined from urinary DNA. HLA specificities not present
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in the recipient’s pretransplant tissue type were assigned to
the donor and results compared with donor HLA type known
from pretransplant typing, to confirm the accuracy of the
urinary HLA type.
Only 3 of the 34 urine samples failed to produce adequate
DNA for tissue typing from 50 ml. Of these, two had been
frozen before processing and one had been left overnight
before DNA was isolated. 8 samples of data, representative of
the 31 patients studied, are shown in Table 1. Of these, one
(patient 15) failed to generate an expected A33 and Cw16.
Two expected alleles in patient 12 were not detected in the
urine, but in each case this was in the context of a technical
failure. Table 2 summarizes the mismatch data in all 31
patients. Patient 15 had undergone two transplants, from the
first of which no donor details were available. No unexpected
alleles were detected from the first kidney but the expected
mismatches from the second graft were all identified.
Across all 31 patients, there were a total of 159
donor–recipient mismatches. Of these, 140 (88%) were
detected from recipient’s urine. Of the 19 (12%) that were
not detected, the internal control reactions failed in all cases
that were thus known to be technical failures. These are
shaded in Table 2. This gave a ‘miss (false negative) rate’ of
a
b
Figure 1 | Representative result of PCR-SSP for HLA class I
typing of recipient urine (a) and blood (b). Each reaction is
shown separately in wells numbered sequentially along the top
row from left to right and then along the bottom row from left to
right (not including the central molecular weight marker lanes).
Those generating a band of appropriate size in each of blood and
urine are marked with a cross. Each well also contains an internal
control reaction yielding a band of 796 bp.
Table 1 | Eight representative samples of deriving donor–recipient HLA mismatches by typing recipient urine
A B Cw DRB1 DRB 3, 4, 5 DQB
Patient 3 (whole blood) 3 24 64 81 8 18 13 18 52 2 4
Donor (whole blood) 24 68 53 81 4 18 13 18 52 2 4
Urine (patient) 3 24 68 53 64 81 4 8 18 13 18 51 52 2 4
Mismatches detected 68 53 4
Patient 4 (whole blood) 2 51 62 10 15 4 13 52 53 6 8
Donor (whole blood) 2 3 7 7 4 7 53 2 8
Urine (patient) 2 3 7 51 62 7 10 15 4 7 13 52 53 2 6 8
Mismatches detected 3 7 7 7 2
Patient 6 (whole blood) 2 51 61 12 14 4 13 52 53 6 7
Donor (whole blood) 2 51 60 10 14 13 52 6
Urine (patient) 2 51 60 61 10 12 14 4 13 52 53 6 7
Mismatches detected 60 10
Patient 7 (whole blood) 1 8 62 7 3 3 4 52 53 2 3
Donor (whole blood) 1 3 27 62 2 3 3 4 52 53 2 3
Urine (patient) 1 3 8 27 62 2 7 3 3 4 52 53 2 3
Mismatches detected 3 27 2
Patient 12 (whole blood) 1 2 7 44 5 7 4 15 51 53 6 8
Donor (whole blood) 2 30 13 44 4 5 4 15 51 53 6 7
Urine (patient) 1 2 30 7 NT 44 NT 5 7 4 15 51 53 6 7 8
Mismatches detected 30 Y Y 7
Patient 15 (whole blood) 2 33 51 58 3 16 4 15 51 53 5 8
Donor (whole blood) 3 11 8 35 4 7 4 15 51 53 6 7
Urine (patient) 2 3 11 8 35 51 58 3 4 7 4 15 51 53 5 6 7 8
Mismatches detected 3 11 X 8 35 4 7 X 6 7
Patient 18 (whole blood) 1 2 8 35 4 7 17 52 2
Donor (whole blood) 1 2 8 35 4 7 17 52 2
Urine (patient) 1 2 8 35 4 7 17 52 2
Mismatches detected
Patient 22 (whole blood) 2 24 40 44 3 16 4 7 53 2 8
Donor (whole blood) 2 30 35 44 8 16 7 15 51 53 2 6
Urine (patient) 2 24 30 35 40 44 3 8 16 4 7 15 51 53 2 6 8
Mismatches detected 30 35 8 15 51 6
Deduction process of donor–recipient HLA mismatches by typing recipient urine. The tissue types above are a serological equivalent of a molecular type. NT: not tested due
to technical failure; X: mismatches not detected in urine typing; Y: mismatches not detected in urine typing, but in context of known inadequate assay.
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0% (that is, where the assay was believed to have been a
technical success). A single false positive (HLA-DRw51 on
patient 3) was detected, a rate of 0.8%.
All 13 control specimens yielded expected tissue typing
(data not shown).
DISCUSSION
This study demonstrates that it is possible to determine
mismatched donor HLA specificities using DNA extracted
from transplanted patients’ urine. We missed no donor–reci-
pient mismatched allele when the internal controls confirmed
an assay was technically successful. Previous work has
focused on methods for the extraction of urinary cell-free
DNA8–10 and its use to predict rejection without biopsy.7,10 The
previous focus of urinary DNA extraction has been the
detection of cancer markers,11,12 DNA polymorphisms,13,14
and infections.15
Urinary DNA can be obtained from cell debris derived
from the cells lining the urinary tracts, including tubules and
bladder,16 so-called ‘transrenal DNA’.17,18 Donor-derived
DNA constitutes a minor proportion (8.7%) of total urinary
DNA,9 but is still readily detectable.
In a few cases, the assay failed on a fresh sample of 50 ml
urine and we could not repeat the typing. However, the
relative ease of obtaining fresh urine samples means that this
should not be a limiting factor in practice. The test’s
simplicity means it is well within the capabilities of any
routine histocompatibility laboratory. DNA can also be
detected from frozen urine when stored appropriately.19
The use of this technique should help in the maintenance
of an accurate patient sensitization history and may also aid
post-transplant monitoring.
MATERIALS AND METHODS
Participants
Ethical approval was obtained from the Hammersmith Hospital
Research Ethics Committee. Samples were collected after informed
consent was granted.
A total of 34 transplant patients with stable creatinine levels
(o10% increase) for 41-year following transplantation were
recruited from the Hammersmith Hospital clinic in 2006. The
control group comprised 13 individuals with no history of renal
pathology or renal transplantation. We excluded infection in that
none had positive urine culture or elevated serum C-reactive protein
at the time of sample collection.
DNA extraction
DNA extraction from fresh urine sample. Fresh, early morning
urine samples (50 ml) were centrifuged (4000 r.p.m., 30 min). DNA
Table 2 | Summary of donor–recipient HLA mismatches using urine samples
Patient no. A B Cw DRB1 DRB3, 4, 5 DQB
No of detected
mismatches
No of expected
mismatches
1 3 27 44 2 5 4 11 52 53 7 8 11 11
2 33 58 10 14 52 5 5 6
3 68 53 4 51a 4 3
4 3 7 7 7 2 5 5
5 0 0
6 60 10 2 2
7 3 27 2 3 3
8 24 68 51 12 15 14 51 5 9 9 9
9 3 38 7 12 4 53 6 3 8 8
10 0 0
11 3 1 14 3 3
12 30 13 4 7 2 4
13 3 32 60 10 4 52 8 7 7
14 3 7 6 7 8 5 5
15 3 11 8 35 4 7 6 7 8 8
16 3 68 35 4 17 52 2 7 7
17 11 35 4 7 4 4
18 0 0
19 31 65 40 3 4 13 53 52 6 8 9 10
20 1 1 1
21 24 18 35 4 14 15 51 5 8 8
22 30 35 8 15 51 6 6 6
23 6 13 2 6 4 4
24 3 35 4 15 51 6 7 7
25 24 29 39 44 16 7 7 5 7
26 1 2 37 5 5 15 51 6 3 8
27 2 26 27 44 1 16 1 7 53 5 5 10
28 23 8 2 3 3
29 7 4 0 2
30 3 68 5 1 5 4 5
31 8 50 2 3 3
Total 141 159
The tissue types above are serological equivalents of a molecular type. The number of detected mismatches includes the single false positive result observed.
Technical problem.
aFalse positive mismatch.
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was extracted from the pellet using QIAamp Viral Mini Kit (Qiagen,
Crawley, UK). (The constituents of buffers AVL, AW1, AW2 and
AVE have not been disclosed by the manufacturer.) Briefly, the pellet
and 250ml supernatant were pulse-vortexed with four volumes of
AVL/RNA carrier buffer (1 ml of buffer AVL to one tube lyophilized
carrier RNA). Following incubation (room temperature, 10 min), an
equal volume of 100% ethanol was added and the sample pulse-
vortexed. The mixture was applied to the QIAamp Spin Column and
centrifuged. The eluate was discarded. Buffer AW1 (500 ml) was
added to the column and centrifuged at 8000 r.p.m. (1 min).
Next, 500ml buffer AW2 was added and centrifuged (14,000 r.p.m.,
3 min). DNA was eluted using five aliquots of 40 ml AVE buffer by
spinning (8000 r.p.m., 1 min), after incubation at room temperature
(1 min).
DNA extraction from whole blood. Genomic DNA was
isolated from whole blood using the Nucleon Genomic DNA
Extraction Kit (Nucleon Biosciences, Manchester, UK) according to
manufacturer’s protocol. EDTA-whole blood (3 ml) was mixed
with Reagent A (17 ml) (10 mM Tris-HCl, 320 mM sucrose, 5 mM
MgCl2, 1%Triton X-100, pH 8.0) and centrifuged (1300 g, 5 min).
The supernatant was discarded and 2 ml reagent B (400 mM
Tris-HCl, pH 8.0, 60 mM EDTA, 150 mM NaCl, 1% SDS) added.
Afterward 500 ml 5 M sodium perchlorate and 2 ml chloroform were
added sequentially and the suspension was centrifuged (1300 g,
1 min). After centrifugation, 200 ml Nucleon Silica Suspension
(Nucleon Biosciences) was added to the aqueous layer and
the sample centrifuged (1300 g, 1 min). Finally, the DNA was
precipitated in ethanol, dissolved in water and adjusted to
30–100 mg/ml.
PCR-SSP HLA class I and II typing
HLA class I typing was performed using 0.15 U Taq polymerase
(Bioline, London, UK), 0.19 mM each dNTP, 5.4 mM MgCl2, and
B25 ng DNA with 6% w/v glycerol and cresol red 0.3 mg. Class II
typing was performed using 0.5 U Taq polymerase (Invitrogen,
Paisley, UK), 0.21 mM dNTP, 2.1 mM MgCl2, andB60 ng DNA with
5% w/v glycerol and cresol red 5.2 mg.
PTC 200 or Perkin Elmer 9600 machines were used.
Cycling conditions for HLA class I and HLA-DQ amplification
were: initial denaturation at 96 1C for 90 s; 6 cycles: 96 1C for
25 s, 70 1C for 50 s, and 72 1C for 45 s; 22 cycles: 96 1C for 25 s,
65 1C for 50 s, and 72 1C for 45 s; 5 cycles: 96 1C for 25 s, 55 1C for
60 s, and 72 1C for 120 s. For HLA-DR typing, the cyclic conditions
were: initial denaturation at 94.0 1C for 25 s; 10 cycles: 94 1C for 25 s,
65 1C for 60 s; 20 cycles: 94 1C for 25 s, 61 1C for 50 s, and 72 1C
for 30 s.
If a reaction failed to amplify a PCR product from its internal
control, the sample was repeated if enough DNA was still available.
Otherwise, it was classified as a ‘failed’ reaction.
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